The direct injection by thoracoscope of mesenchymal stem cells (MSCs) that had been genetically modified to express angiopoietin-1 was investigated in a porcine model to determine their effect on arteriogenesis and the effectiveness of this technique. Chronic myocardial ischaemia was established using a thoracoscope to insert an ameroid constrictor around the left circumflex coronary artery. Six weeks after establishing the ischaemia, 20 pigs were randomly divided into three groups to receive injections by thoracoscope of either genetically-modified MSCs, unmodified MSCs or phosphate-buffered saline into the ischaemic border area. The injections were repeated 1 month later. The genetically modified MSCs were found to restore blood flow significantly more than the other observed treatments and immunohistochemical evaluation of arteriogenesis supported this finding. In conclusion, the injection of MSCs that had been genetically modified to express angiopoietin-1 improved arteriogenesis and increased collateral blood flow in the myocardial ischaemic area. Thoracoscope delivery of the injection was safe and minimally invasive.
Introduction
Despite considerable progress in the development of interventional treatments for chronic ischaemia of the heart, including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty, new and improved approaches are still required for the treatment of restenosis of coronary arteries and for heart failure. 1, 2 In the last decade, numerous studies have investigated the possibility of using the protein or gene of individual vascular growth factors, including vascular endothelial growth factor (VEGF), 3 -11 fibroblast growth factor 2 12 -15 and angiopoietin-1 in combination with SL Chen, CC Zhu, YQ Liu et al. Mesenchymal stem cell enhancement of angiogenesis VEGF 16, 17 or alone, 18 to improve angiogenesis in myocardial-and limb-muscle ischaemic areas. This area of research remains controversial, however, mainly because little arteriogenesis has been observed in these various angiogenic growth factor studies.
Arteriogenesis, which is the process of remodelling pre-existing small arterioles into larger mature vessels, involves the coordinated effects of a huge number of growth factors and the recruitment of mural cells to form the muscular blood vessel walls. 17, 19, 20 The main aim of biological therapiesincluding gene and cell therapies -in mitigating chronic myocardial ischaemia is, therefore, to induce arteriogenesis, rather than just to stimulate angiogenesis which, although characterized by new capillary formation, does not result in larger arteriole formation in the ischaemic area. 1, 2, 21 However, the mechanism of arteriogenesis in large animals and humans is not fully understood. 1, 21 Angiopoietin-1 is considered to be one of the most important vascular growth factors involved in arteriogenesis. 20, 22 Its functions include mediating neovessel maturation into more complex and larger vascular structures, and maintaining vessel integrity during the recruitment of peri-endothelial cells and the remodelling of the basement membrane. Due to the complex mechanism of arteriogenesis, a new therapeutic strategy that might be a promising approach to enhance arteriogenesis and improve perfusion in ischaemic myocardium involves the utilization of bone marrow stromal cell therapy. 23, 24 Mesenchymal stem cells (MSC) have been shown to differentiate into both endothelial cells and myocytes after being placed in a myocardial ischaemic region. 25 Research has also shown that bone marrow stem cells are recruited by angiopoietin-1 into the ischaemic tissue and incorporated into blood vessel walls. 20 The aim of the present study was to establish a porcine model of chronic coronary ischaemia by blocking the left circumflex (LCX) coronary artery using ameroid constrictors inserted through a thoracoscope and then to inject MSCs that had been genetically modified with the angiopoietin-1 gene into the ischaemic tissue border zone with a view to looking at the effects on heart function, arteriogenesis of collateral blood vessels and expression of angiopoietin-1.
Materials and methods

ANIMALS AND EXPERIMENTAL PROCEDURE
All animal treatment and care was undertaken according to Guidelines for the Care and Use of Experimental Animals published by the Medical Science Association of JiangSu Province, China. Twenty-three pigs, each weighing 12 -15 kg, were pre-medicated and anaesthetized with pentobarbital sodium. Anaesthesia was maintained by inhalation of 2 -3% enflurane.
A model of establishing chronic myocardial ischaemia through a thoracoscope was used to mimic clinical chronic myocardial ischaemia. 15, 26, 27 In brief, three pores each approximately 1 cm in diameter were made through the left wall of the chest during the first operation: the pore at the cross point of the third intercostal space and the left posterior axillary line was for a trocar camera; the main operating pore was at the cross point of the second intercostal space and the left-side sternal line; and the assistant operating pore was at the cross point of the fourth intercostal space and the left mid-clavicular line. The pericardium was opened through a thoracoscope and the LCX coronary artery was dissected free. An ameroid constrictor (Research Instruments NW Inc., Sweethome, OR, USA) with an internal diameter of 2.0 mm was placed SL Chen, CC Zhu, YQ Liu et al.
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around the LCX coronary artery in the same location for each animal. The pericardium and the pores were all closed. Intramuscular injection of 1.6 × 10 6 U of penicillin twice a day continued for 5 days from the operation day for prevention of infection.
Six weeks after the first operation, heart function, the ischaemic zone sizes and collateral blood vessel development were evaluated before the cell therapy was administered through a thoracoscope during a second operation. Twenty pigs were randomized into three groups to receive different therapeutic approaches: seven pigs received MSCs genetically modified with the angiopoietin-1 gene injected directly into the myocardial ischaemic border area (MSC + Ang-1 group); seven pigs received unmodified MSCs injected directly into the myocardial ischaemic border area (MSC group); and six pigs received an injection of phosphate buffered-saline (PBS) into the myocardial ischaemic border area (control group). One month later the second operation was repeated to administer a second dose of cell therapy. The three remaining pigs were used for MSC isolation.
Peri-and post-operative care after the second and repeat operations was the same as after the first operation and the animals were fed as normal until they were sacrificed for histological evaluation 12 weeks after administration of the first cell therapy dose. Heart function examinations were performed every 4 weeks after the cell therapy operations.
BONE MARROW MSC ISOLATION AND PRIMARY CULTURE
Bone marrow-derived MSCs were isolated and cultured from the three untreated pigs that were not used in the model to establish chronic myocardial ischaemia, according to a previously reported method. 28 -30 In brief, bone marrow plugs were extracted by flushing the bone marrow cavity with Dulbecco's Modified Eagle's Medium -Low Glucose (DMEM-LG; Gibco™, Gaithersburg, MD, USA). Mononucleated cells were isolated from the perfusates by density gradient fractionation (1.073 g/ml Percoll™; Pharmacia, Piscataway, NJ, USA), washed and resuspended in DMEM-LG supplemented with 10% fetal bovine serum, and cultured at 37°C in a humidified atmosphere containing 5% CO 2 . The MSC population was isolated on the basis of its ability to adhere to the culture plate. When the cultures reached 90% confluence the cells were passaged and were used in the experiments after two to four passages.
ADENO-ASSOCIATED VIRAL VECTOR
The adeno-associated viral (AAV) vector, which was constructed by the Vector Gene Technology Company (Beijing, China), was based on the pSNAV plasmid containing angiopoietin-1 cDNA. Viral preparations used in this study for MSC transduction had titres with 1 × 10 14 viral genome particles/ml.
ANGIOPOIETIN-1 GENE TRANSFER AND PREPARATION OF MSCS
The MSCs were transfected with AAV-angiopoietin-1 or empty vector as described previously. 28, 31 Those MSCs that had been genetically modified to express angiopoietin-1 were identified by combining reporter gene green fluorescent protein (GFP) with the transfected gene and use of fluorescence microscopy as described previously. 28 The expression of angiopoietin-1 in cell culture was analysed by an enzymelinked immunosorbent assay (ELISA kit for detection of human angiopoietin-1; JinMei Company, Shenzheng, China). The suspension of MSCs was mixed with heparin, then filtered and prepared for implantation. The final concentration of the MSCs was 4 × 10 7 cells/ml.
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MEASUREMENT OF ANGIOPOIETIN-1 PROTEIN AND MRNA EXPRESSION
Expression of human angiopoietin-1 protein and mRNA by AAV-angiopoietin-1 transfected MSC was confirmed by measurement of immunoreactive human angiopoietin-1 by Western blotting 22, 25 and reverse transcription polymerase chain reaction (RT-PCR) 22, 25 , respectively.
ECHOCARDIOGRAPHY
Echocardiography was performed by an experienced echocardiographer (blinded to the treatment group details) on the day before the first operation to establish myocardial ischaemia and 4, 8 and 12 weeks after the injection of MSCs + Ang-1, MSCs or PBS. All images were obtained using a Hewlett-Packard 5500 ultrasound system and 12-MHz probe (Hewlett-Packard, Palo Alto, CA, USA). The ejection fraction (EF), fractional shortening (FS) and left ventricular (LV) systolic and diastolic areas were calculated.
The left ventricle was assessed in both parasternal long-axis and short-axis views. Right parasternal long-axis views were used to obtain two-dimensional (2-D) measurements of the EF. The 2-D EF was derived from manually traced ventricular areas at end diastole and end systole. Using the right 2-D parasternal short-axis imaging plane as a guide, an LV M-mode tracing was obtained at the base, mid-papillary region and apex. The M-mode measurements were obtained at each level from which FS was derived. End-diastolic and end-systolic dimensions of the LV cavity (LVDd and LVDs, respectively) were measured inside the infarct area in the M-mode. The EF values were calculated and used as an indicator of ventricular function, as follows: EF (%) = (0.85LVAd 2 /LVLd) -(0.85LVAs 2 /LVLs) × 100 (0.85LVAd 2 /LVLd) where LVAd is the left ventricular area of the end-diastolic stage, LVLd is the left ventricular long-axis of the end-diastolic stage, LVAs is the left ventricular area of the end-systolic stage, and LVLs is the left ventricular longaxis of the end-systolic stage.
CORONARY ARTERY ANGIOGRAPHY
The formation of collateral blood vessels in the ischaemic area was examined by angiography. Selective left coronary artery angiography was performed with a manual injection of 5 ml of 60% meglumine diatrizoate at a flow rate of 1 ml/s. Vascularization of the left ventricular collateral vessels was recorded continuously and analysed by a previously described method. 32 Angiographic assessment was scored as follows: 0, no visualization of meglumine diatrizoate in the distal LCX coronary artery; 1, visualization of meglumine diatrizoate but not filling the distal LCX coronary artery; 2, visualization of meglumine diatrizoate and filling the distal LCX coronary artery needed > 3 pulses of blood; 3, visualization of meglumine diatrizoate and filling the distal LCX coronary artery needed ≤ 3 pulses of blood.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
For histological evaluation, the animals were sacrificed at 12 weeks after the first cell therapy injection and the left ventricular tissue was harvested, fixed in 2% formaldehyde and embedded in paraffin.
Areas of arteriole muscle wall were measured and marked throughout the whole of the left ventricle. Immunohistochemical detection of arterioles was performed using an Avidin-Biotin complex kit (Vector Laboratories, Burlingame, CA, USA) as described previously. 16 Detection of the immunohistochemical marker, α-smooth SL Chen, CC Zhu, YQ Liu et al. Mesenchymal stem cell enhancement of angiogenesis muscle actin, was carried out using the antiswine antibody of α-smooth muscle actin purchased from JinMei Company. Rabbit anti-swine was used as the secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After the series of treatments, slides were stained with 3,3′-diaminobenzidine as the detection agent.
STATISTICAL ANALYSIS
All data were presented as mean ± SD. Oneway analysis of variance was used to compare differences in arteriogenesis and left ventricular function between the three groups. Paired t-tests were performed when appropriate for comparison with baseline data before the operation and after cell therapy. A P-value < 0.05 was considered statistically significant.
Results
Mortality rates in the early stage of the operation and in the later stages after cell therapy were not significantly different among the three groups (data not shown). Eighteen animals survived for the duration of the study. This higher survival rate observed in the present study compared with those of our previous study (unpublished) of the porcine ischaemia model established via thoracotomy was probably due to less damage because of the use of a thoracoscope during the operation.
EXPRESSION OF REPORTER GENE AND ANGIOPOIETIN-1 PROTEIN AND MRNA
The AAV-angiopoietin-1 transfected MSC expressed human angiopoietin-1 protein, which was confirmed by the production of immunoreactive human angiopoietin-1 as measured by Western blotting (data not shown). The expressions of angiopoietin-1 protein and mRNA were also detected by ELISA assay and RT-PCR (data not shown).
The MSCs that had been genetically modified with angiopoietin-1 were identified by reporter gene GFP expression, which was combined with the transfected gene. A representative fluorescent micrograph of GFP-positive MSCs is shown in Fig. 1 .
ECHOCARDIOGRAPHY RESULTS
The EF and FS data for the three groups are shown in Tables 1 and 2 , respectively, and indicate improvement in left ventricular function after cell therapy with MSCs transfected with the angiopoietin-1 gene. Echocardiographic measurements of the segmental contraction revealed hypokinesis of the ischaemic zone after placement of the ameroid constrictor on the LCX coronary artery, and showed that cell therapy with MSCs transfected with angiopoietin-1 had a significant restorative effect in this porcine model of chronic myocardial ischaemia. Although there was improvement of heart function as measured by the echocardiography results over the 12-week 
ANGIOGRAPHIC ASSESSMENT
Angiographic findings demonstrated collateral artery and neovascular formation in the ischaemic myocardium of all treatment groups. Assessment of angiographic scores before the second operation which administered MSCs or PBS showed no difference between the three groups. At 12 weeks after first cell therapy dose the group that had been given MSCs transfected with angiopoietin-1 demonstrated a significant increase in angiographic scores compared with the group given unmodified MSCs and the PBS-treated control group (Table 3) , indicating significantly larger diameter arteries. A typical angiogram of the group given MSCs transfected with angiopoietin-1 is shown in Fig. 2 .
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ASSESSMENTS
In agreement with the angiographic scores, 
TABLE 1: Ejection fraction (EF%, mean ± SD) as measured by echocardiography in a porcine model of myocardial ischaemia following injection of mesenchymal stem cells (MSCs) transfected with the angiopoietin-1 (Ang-1) gene (MSC + Ang-1), unmodified MSCs (MSC) or phosphate buffered saline (control) directly into the ischaemic zone TABLE 2: Fractional shortening (FS%, mean ± SD) as measured by echocardiography in a porcine model of myocardial ischaemia following injection of mesenchymal stem cells (MSCs) transfected with the angiopoietin-1 (Ang-1) gene (MSC + Ang-1), unmodified MSCs (MSC) or phosphate buffered saline (control) directly into the ischaemic zone
Post-operation
Group
Pre-operation 4 weeks 8 weeks 12 weeks a 
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the group given MSCs transfected with angiopoietin-1 showed a capillary density at 12 weeks after the first therapy of 1051. 18 ± 198 .57 /mm 2 (P = 0.015 versus PBS-treated control) and 839.92 ± 154.76 /mm 2 in the group given unmodified MSCs (P = 0.022 versus PBS-treated control). The capillary density in the PBS-treated control group at 12 weeks was 689.25 ± 120.39 /mm 2 . There was no significant difference between the group given unmodified MSCs and the group given MSCs transfected with angiopoietin-1.
The number of α-smooth muscle actin positive vessels with diameters > 10 µm, indicative that they were mature smooth muscle walled arterioles, was significantly higher at 8 weeks after the first therapy in the group treated with MSCs transfected with angiopoietin-1 (90.23 ± 27.85 /mm 2 ) than in the unmodified MSC (75.61 ± 24.06 /mm 2 ; P = 0.04) and control groups (68.36 ± 18.85 /mm 2 ; P = 0.02) (Fig. 3) .
Post-operation
Group 4 weeks 8 weeks 12 weeks a
Control 0/6 0/6 0/6 MSC 0/7 1/7 1/7 MSC + Ang-1 0/7 1/7 5/7
One or two grade improvement in the angiographic score was considered as positive evidence of left circumflex (LCX) coronary artery collateral formation. a At 12 weeks post-operation: P = 0.008 MSC + Ang-1 versus control; P = 0.036 MSC + Ang-1 versus MSC; MSC versus control not statistically significant (P > 0.05). 
TABLE 3: The effect of injection of mesenchymal stem cells (MSCs) transfected with the angiopoietin-1 (Ang-1) gene (MSC + Ang-1), unmodified MSCs (MSC) or phosphate buffered saline (control) directly into the ischaemic zone on the angiographic score in a porcine model of myocardial ischaemia
Discussion
Direct injection of autologous MSCs into muscle-walled vessels in the region of ischaemic tissues is a promising therapeutic strategy that provides high levels of angiogenic cytokines to stimulate angiogenesis and arteriogenesis. 28, 31, 33 Transplantation of MSCs has been found to facilitate myocardial reconstruction and restore lost heart function in animal models and clinical trials. 34 -37 Several studies have indicated that genetically engineered MSCs carrying VEGF could improve revascularization in a model of acute myocardial infarction. 34, 37 The findings of the present study suggest that modified MSCs transfected with the angiopoietin-1 gene have the capacity to improve the formation of arterioles and enlarge collateral vessels at 12 weeks after direct cell injection.
The angiographic scores were significantly higher following injection with MSCs transfected with angiopoietin-1 than after either unmodified MSC or PBS injections. Similarly, the histological assessment of α-smooth muscle actin, which is a marker of smooth muscle cells in arteriole walls, demonstrated a significantly higher expression in the group injected with MSCs transfected with angiopoietin-1 than in either the unmodified MSC-injected or PBS-injected groups. In addition, left ventricular function was enhanced following SL Chen, CC Zhu, YQ Liu et al.
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injection with MSCs transfected with angiopoietin-1.
The benefits associated with the injections of MSCs transfected with angiopoietin-1 on this porcine ischaemic myocardium model were based on the combined effects of the MSCs and the angiogenic factor. First, angiopoietin-1 can recruit circulating MSCs into the ischaemic zone or infarction area. 23 -25 Secondly, MSCs can produce numerous vascular growth factors including angiopoietin-1, VEGF, fibroblast growth factor and hepatocyte growth factor, which are involved not only in the early stage of angiogenesis but also in the later stage of arteriogenesis. 21 Finally, and most importantly, the MSCs that are directly injected into the myocardial ischaemic area can incorporate themselves into new vessels and function as supportive cells for neovascularization. 23, 36 Regardless of the precise mechanism of action, the delivery of genetically modified MSCs appears to increase tissue perfusion. Whether cell therapy can overcome several potential limitations, such as the low survival rate of cells after local transplantation into ischaemic zones, is still not known. The present study was designed and performed using a thoracoscope which allowed direct injection of the genetically modified MSCs directly into the myocardial ischaemic area and, because this is a minimally invasive technique, it enabled the MSCs to be injected twice with just 1-month between injections. Contractility of the left ventricle, as measured by EF and FS, was significantly enhanced in the two MSC groups (unmodified MSC group and the MSC group transfected with angiopoietin-1) in the present study. Unexpectedly, the PBS-treated control group also showed a slight improvement of left ventricle function at 12 weeks, indicating a self-restorative effect.
Angiopoietin-1 is a growth factor that can induce endothelial migration and sprouting, and recruit endothelial progenitor cells or MSCs into the ischaemic zone. Furthermore, it can work in concert with other cytokines to stimulate the formation of pericytes and smooth muscle cells, leading to the maturation and stability of new blood vessels. For example, Thurston et al. 20, 22 reported that angiopoietin-1 over-expression induced an increase in capillary density in normal and ischaemic myocardium; interestingly, arteriole density increased only in the ischaemic post-infarction myocardium. Consistent with these previous studies, the results of the present study also showed that arteriole density increased in the group treated with MSCs transfected with angiopoietin-1, as measured by angiography and immunohistochemical staining of α-smooth muscle actin. The most obvious effect of treatment with MSCs transfected with angiopoietin-1 compared with the other two groups was in angiopoietin-1 induced arteriole formation, an effect that was probably due to the cytokine effect of angiopoietin-1 in the enlargement of blood vessels and differentiation into new myocytes.
To the authors' knowledge this is the first report of thoracoscopy being used to establish chronic ischaemic myocardium in a porcine model and for the delivery of genetically modified MSCs. Our previous study found that mini-thoracoscopy was less damaging to the ischaemic myocardium animal model (unpublished data). The major problem for patients in clinical trials of gene or cell therapy is the fact that repeated operations are unacceptable, however thoracoscopy might provide an effective route for administering angiogenesis therapy that might be acceptable not only in clinical trials but even for clinical practice owing to its minimally invasive nature. In summary, the present study has demonstrated that functional arteriogenesis and collateral blood vessels can be achieved by the direct administration of MSCs that have been genetically modified to express angiopoietin-1. While there is no long-term activity of MSCs after local delivery, the cell therapy was administered twice using a thoracoscope and, importantly, the MSCs and angiopoietin-1 appeared to work in concert to stimulate collateral vessel formation and the production of new myocytes, and this is likely to maintain prolonged formation of larger, more mature collateral vessels, thus increasing myocardial perfusion.
